Poster Oral Presentation 2

[PO-018] Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study

*Silvio Danese¹, Raymond K. Cross², Douglas C. Wolf³, Katsuyoshi Matsuoka⁴, Iris Dotan⁵, Brigid S. Boland⁶, Laura E. Raffals⁷, Dimpy Mehra⁸, Norma Ruiz Santiago⁸, AnnKatrin Petersen⁸, Manik Desai⁸, Hsiuanlin Wu⁸, Dong Wang⁹, Mark T. Osterman⁸, Anjali Jain⁸, James O. Lindsay¹⁰ (1. Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy, 2. Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy Medical Center, Baltimore, MD, USA, 3. Center for Crohn’s Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, GA, USA, 4. Toho University Sakura Medical Center, Sakura, Chiba, Japan, 5. The Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, 6. Department of Medicine, University of California San Diego, La Jolla, CA, USA, 7. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, 8. Bristol Myers Squibb, Princeton, NJ, USA, 9. Bristol Myers Squibb K. K., Tokyo, Japan, 10. Barts and the London School of Medicine and Dentistry, London, UK)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.